Home › Companies › MOONLAKE IMMUNOTHERAPEUTICS › 2023-2024

MOONLAKE IMMUNOTHERAPEUTICS 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed 2024-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
125Asset managers
900Fund votes
2024-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MOONLAKE IMMUNOTHERAPEUTICS in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by MOONLAKE IMMUNOTHERAPEUTICS

These tallies are MOONLAKE IMMUNOTHERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MOONLAKE IMMUNOTHERAPEUTICS — official shareholder meeting results, meeting held 2024-06-05
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: ● Catherine Moukheibir	50,398,781	--	--	4,335,564	4,241,512	Majority: yes
Elect Director: ● Dr. Ramnik Xavier	53,899,047	--	--	835,298	4,241,512	Majority: yes

Source: MOONLAKE IMMUNOTHERAPEUTICS, Form 8-K, filed with the SEC on 2024-06-06 — read the filing on EDGAR.

How asset managers voted at the MOONLAKE IMMUNOTHERAPEUTICS 2023-2024 meeting

Each item below shows how the 125 asset managers that disclosed a MOONLAKE IMMUNOTHERAPEUTICS vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of MOONLAKE IMMUNOTHERAPEUTICS’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval of, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 120 asset managers below cast 100% of the shares they voted on this item FOR (55,467,067 for, 0 against).

FOR: 55,467,067 (100.0%)ABSTAIN: 6,160 (0.0%)NOT VOTED: 4,768 (0.0%)

Largest asset managers voting on “Approval of, on an advisory basis, the compensation of the Company's named executive officers.” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Vote
BVF INC/IL	21,751,284	For
Cormorant Asset Management, LP	6,670,937	For
Fidelity	5,894,517	For
T. Rowe Price	5,588,061	For
Avoro Capital Advisors LLC	2,580,000	For
Citadel	2,188,652	For
AllianceBernstein	1,217,248	For
Polar Capital Holdings Plc	853,968	For
Federated Hermes	844,460	For
WESTFIELD CAPITAL MANAGEMENT CO LP	709,545	For
FRED ALGER MANAGEMENT, LLC	662,786	For
ALGER FUNDS	548,604	For
MARSHALL WACE, LLP	452,580	For
PICTET ASSET MANAGEMENT SA	427,557	For
HARBOR FUNDS	405,159	For
Finepoint Capital LP	360,916	For
BlackRock	315,061	For
MPM BioImpact LLC	300,165	For
BALYASNY ASSET MANAGEMENT L.P.	295,941	For
5AM Venture Management, LLC	282,313	For
Candriam S.C.A.	239,000	For
AB DISCOVERY GROWTH FUND, INC.	204,803	For
Woodline Partners LP	203,407	For
Nuveen	190,048	For
Wellington	177,961	For

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

2. NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

1-YR 39%ONE YEAR 38%1 YEAR 22%

The 118 asset managers below cast 100% of the shares they voted on this item FOR (921 for, 0 against).

FOR: 921 (0.0%)ABSTAIN: 6,160 (0.0%)1-YR: 21,751,284 (39.2%)ONE YEAR: 21,153,067 (38.1%)1 YEAR: 12,435,276 (22.4%)1-YEAR: 63,298 (0.1%)3 YEARS: 62,282 (0.1%)NOT VOTED: 4,768 (0.0%)

Largest asset managers voting on “NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION.” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
BVF INC/IL	0	0	0	0	1-Yr
Cormorant Asset Management, LP	0	0	0	0	1 Year
Fidelity	0	0	0	0	One Year
T. Rowe Price	0	0	0	0	One Year
Avoro Capital Advisors LLC	0	0	0	0	1 Year
Citadel	0	0	0	0	One Year
AllianceBernstein	0	0	0	0	One Year
Polar Capital Holdings Plc	0	0	0	0	One Year
Federated Hermes	0	0	0	0	1 Year
WESTFIELD CAPITAL MANAGEMENT CO LP	0	0	0	0	One Year
FRED ALGER MANAGEMENT, LLC	0	0	0	0	One Year
ALGER FUNDS	0	0	0	0	One Year
MARSHALL WACE, LLP	0	0	0	0	1 Year
PICTET ASSET MANAGEMENT SA	0	0	0	0	One Year
HARBOR FUNDS	0	0	0	0	1 Year
Finepoint Capital LP	0	0	0	0	One Year
BlackRock	0	0	0	0	One Year
MPM BioImpact LLC	0	0	0	0	1 Year
BALYASNY ASSET MANAGEMENT L.P.	0	0	0	0	1 Year
5AM Venture Management, LLC	0	0	0	0	1 Year
Candriam S.C.A.	0	0	0	0	One Year
AB DISCOVERY GROWTH FUND, INC.	0	0	0	0	One Year
Woodline Partners LP	0	0	0	0	One Year
Nuveen	0	0	0	0	One Year
Wellington	0	0	0	0	1 Year

Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.

3. Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Catherine Moukheibir

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 50,398,781WITHHELD: 4,335,564

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: ● Catherine Moukheibir”): 50,398,781 for, 4,335,564 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,637,212 outstanding shares: 80% for, 7% withheld (87% of the company cast a for/withheld vote).

The 44 asset managers below cast 100% of the shares they voted on this item FOR (7,312,399 for, 0 against).

FOR 92%8%

FOR: 7,312,399 (92.3%)ABSTAIN: 610,186 (7.7%)

Largest asset managers voting on “Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders ” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Abstain	Vote
T. Rowe Price	2,417,042	0	For
Fidelity	2,316,557	0	For
ALGER FUNDS	0	548,604	Abstain
Federated Hermes	411,035	0	For
HARBOR FUNDS	405,159	0	For
AllianceBernstein	339,802	0	For
BlackRock	252,865	0	For
AB DISCOVERY GROWTH FUND, INC.	204,803	0	For
TimesSquare Capital Management, LLC	172,881	0	For
TIAA	166,939	0	For
Equitable	86,518	0	For
Vanguard	75,958	0	For
Principal	71,490	0	For
Victory Capital	58,371	0	For
Bridge Builder Trust	47,487	0	For
John Hancock	41,526	0	For
Northwestern Mutual	31,128	0	For
ALGER PORTFOLIOS	0	30,605	Abstain
Lord Abbett	26,171	0	For
Harbor Funds II	25,757	0	For
ALGER INSTITUTIONAL FUNDS	0	24,817	Abstain
Jackson National	24,311	0	For
State Street	23,232	0	For
Nushares ETF Trust	23,109	0	For
Brighthouse	11,619	6,160	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

4. Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders and until their successors are duly elected and qualified: Dr. Ramnik Xavier

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 53,899,047WITHHELD: 835,298

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“Elect Director: ● Dr. Ramnik Xavier”): 53,899,047 for, 835,298 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,637,212 outstanding shares: 86% for, 1% withheld (87% of the company cast a for/withheld vote).

The 44 asset managers below cast 100% of the shares they voted on this item FOR (7,312,399 for, 0 against).

FOR 92%8%

FOR: 7,312,399 (92.3%)ABSTAIN: 610,186 (7.7%)

Largest asset managers voting on “Election of the two Class II director nominees to serve until the 2027 Annual General Meeting of Shareholders ” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Abstain	Vote
T. Rowe Price	2,417,042	0	For
Fidelity	2,316,557	0	For
ALGER FUNDS	0	548,604	Abstain
Federated Hermes	411,035	0	For
HARBOR FUNDS	405,159	0	For
AllianceBernstein	339,802	0	For
BlackRock	252,865	0	For
AB DISCOVERY GROWTH FUND, INC.	204,803	0	For
TimesSquare Capital Management, LLC	172,881	0	For
TIAA	166,939	0	For
Equitable	86,518	0	For
Vanguard	75,958	0	For
Principal	71,490	0	For
Victory Capital	58,371	0	For
Bridge Builder Trust	47,487	0	For
John Hancock	41,526	0	For
Northwestern Mutual	31,128	0	For
ALGER PORTFOLIOS	0	30,605	Abstain
Lord Abbett	26,171	0	For
Harbor Funds II	25,757	0	For
ALGER INSTITUTIONAL FUNDS	0	24,817	Abstain
Jackson National	24,311	0	For
State Street	23,232	0	For
Nushares ETF Trust	23,109	0	For
Brighthouse	11,619	6,160	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

5. Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (7,916,425 for, 0 against).

FOR: 7,916,425 (99.9%)ABSTAIN: 6,160 (0.1%)

Largest asset managers voting on “Ratification, by ordinary resolution, of the selection of Baker Tilly US, LLP as the Company's independent reg” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Abstain	Vote
T. Rowe Price	2,417,042	0	For
Fidelity	2,316,557	0	For
ALGER FUNDS	548,604	0	For
Federated Hermes	411,035	0	For
HARBOR FUNDS	405,159	0	For
AllianceBernstein	339,802	0	For
BlackRock	252,865	0	For
AB DISCOVERY GROWTH FUND, INC.	204,803	0	For
TimesSquare Capital Management, LLC	172,881	0	For
TIAA	166,939	0	For
Equitable	86,518	0	For
Vanguard	75,958	0	For
Principal	71,490	0	For
Victory Capital	58,371	0	For
Bridge Builder Trust	47,487	0	For
John Hancock	41,526	0	For
Northwestern Mutual	31,128	0	For
ALGER PORTFOLIOS	30,605	0	For
Lord Abbett	26,171	0	For
Harbor Funds II	25,757	0	For
ALGER INSTITUTIONAL FUNDS	24,817	0	For
Jackson National	24,311	0	For
State Street	23,232	0	For
Nushares ETF Trust	23,109	0	For
Brighthouse	11,619	6,160	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

6. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 99.9%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 1,883,296 (100.0%)ONE YEAR: 382 (0.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	0	0	0	1-Year
Desjardins Global Asset Management Inc.	0	0	0	0	One Year

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,883,678 for, 0 against).

FOR: 1,883,678 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at MOONLAKE IMMUNOTHERAPEUTICS, 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,883,296	0	0	0	For
Desjardins Global Asset Management Inc.	382	0	0	0	For

Largest MOONLAKE IMMUNOTHERAPEUTICS shareholders voting in 2023-2024

Ranked by the number of MOONLAKE IMMUNOTHERAPEUTICS shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 62,637,212 shares outstanding at the time of that meeting.

Top MOONLAKE IMMUNOTHERAPEUTICS shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	BVF INC/IL	34.73%
2	Cormorant Asset Management, LP	10.65%
3	Fidelity	9.41%
4	T. Rowe Price	8.92%
5	Avoro Capital Advisors LLC	4.12%
6	Citadel	3.49%
7	AllianceBernstein	1.94%
8	Polar Capital Holdings Plc	1.36%
9	Federated Hermes	1.35%
10	WESTFIELD CAPITAL MANAGEMENT CO LP	1.13%

Reported MOONLAKE IMMUNOTHERAPEUTICS ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

MOONLAKE IMMUNOTHERAPEUTICS beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Certain funds managed by BVF Partners L.P.	34.73%	DEF14A
Entities affiliated with Bihua Chen	13.56%	DEF14A
Entities affiliated with FMR LLC	6.14%	DEF14A
Dr. Jorge Santos da Silva	4.76%	DEF14A
Dr. Kristian Reich	4.74%	DEF14A
Citadel Advisors	3.78%	13F
T. Rowe Price	3.41%	13F
FMR (Fidelity)	1.16%	13F
Matthias Bodenstedt	0.83%	DEF14A
Simon Sturge	0.61%	DEF14A

Percentages above are of 62,637,212 shares outstanding, as reported by MOONLAKE IMMUNOTHERAPEUTICS on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MOONLAKE IMMUNOTHERAPEUTICS’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At MOONLAKE IMMUNOTHERAPEUTICS's shareholder meeting held 2024-06-05, in the 2023-2024 proxy season, 125 asset managers reported how they voted in their SEC Form N-PX filings, covering 900 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. MOONLAKE IMMUNOTHERAPEUTICS's own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval of, on an advisory basis, the compensation of the Company's named executive officers. — the reporting funds cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

MOONLAKE IMMUNOTHERAPEUTICS proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.